Perrigo (PRGO) Updates FY18 Earnings Guidance
Perrigo (NYSE:PRGO) updated its FY18 earnings guidance on Thursday. The company provided earnings per share guidance of $4.75-4.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.21.
A number of analysts have recently issued reports on the company. Royal Bank of Canada set a $67.00 target price on Perrigo and gave the stock a hold rating in a report on Friday. Stifel Nicolaus decreased their target price on Perrigo from $92.00 to $87.00 and set a hold rating for the company in a report on Friday. Canaccord Genuity set a $105.00 target price on Perrigo and gave the stock a buy rating in a report on Monday, May 14th. ValuEngine upgraded Perrigo from a sell rating to a hold rating in a report on Wednesday. Finally, Cantor Fitzgerald set a $107.00 price target on Perrigo and gave the stock a buy rating in a report on Thursday. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the company’s stock. Perrigo presently has a consensus rating of Hold and an average price target of $89.94.
NYSE PRGO opened at $69.90 on Friday. The company has a market capitalization of $10.84 billion, a price-to-earnings ratio of 15.20, a P/E/G ratio of 1.84 and a beta of 0.84. Perrigo has a fifty-two week low of $67.69 and a fifty-two week high of $95.93. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.08 and a quick ratio of 1.48.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 18th. Shareholders of record on Friday, August 31st will be issued a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date of this dividend is Thursday, August 30th. Perrigo’s dividend payout ratio is presently 15.42%.
In other Perrigo news, Director Jeffrey C. Smith bought 50,000 shares of Perrigo stock in a transaction dated Thursday, May 17th. The stock was bought at an average cost of $75.89 per share, for a total transaction of $3,794,500.00. Following the purchase, the director now owns 528 shares in the company, valued at approximately $40,069.92. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey C. Smith bought 250,000 shares of Perrigo stock in a transaction dated Tuesday, May 15th. The shares were acquired at an average price of $75.21 per share, with a total value of $18,802,500.00. Following the completion of the purchase, the director now owns 528 shares in the company, valued at approximately $39,710.88. The disclosure for this purchase can be found here. Corporate insiders own 6.90% of the company’s stock.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Further Reading: Are Wall Street analysts’ stock ratings worth following?
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.